Welcome to Shift by Alberta Innovates.
On this episode we speak with Dr. John Lewis from Edmonton-based ENTOS pharmaceuticals about their journey toward creating a made-in-Alberta vaccine for Covid-19.
John walks us through how he and his team's work on genetic medications as a treatment for metastatic cancer created an opportunity to develop a potential Covid vaccine using their proprietary Fusogenix genetic medicines delivery platform.
Along the way we discuss the steps within a clinical trial, how researchers from "competing" labs work together for everyone's benefit, the implications of the much used phrase "fast tracking" when it comes to the development of medical interventions, his work on something called tumor glue, and much more.
But don't our word for it. Grab seat, click play and learn more about the Journey to Conquer Covid.
BIO
John D. Lewis, Ph.D, founder, Chief Executive Officer of Entos Pharmaceuticals
John is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta in Edmonton, Alberta.
A scientist and serial entrepreneur, his research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer.
He has pioneered the use of intravital imaging to discover key therapeutic targets in cancer.
Shift by Alberta Innovates focuses on the people, businesses and organizations that are contributing to Alberta's strong tech ecosystem.